Gold prices slip after rallying on Powell rate cut talk
Klotho Neurosciences, Inc. (NASDAQ:KLTO), a biotech firm focused on biological products, announced today that it has amended the terms of its April 2022 Public Warrant. The amendment introduces a temporary change in the exercise price of the warrants, offering a limited-time opportunity for warrant holders. The company, currently trading at $2.01 and showing significant volatility, has seen its stock surge over 1,000% in the past week. According to InvestingPro analysis, the stock’s RSI indicates overbought conditions.
According to the company’s recent 8-K filing with the Securities and Exchange Commission, the exercise price of the Public Warrants has been reduced to $1.35 for a short window, starting at 9:30 AM on Monday, June 10, 2025, until 4:00 PM on June 20, 2025, Eastern Time. Post this period, known as the Effective Date Range, the exercise price will revert to its previous amount of $3.49. This move is designed to incentivize the exercise of warrants during this ten-day period. With a market capitalization of $65.31 million and an overall weak financial health score according to InvestingPro, the company faces challenges with its current ratio of 0.29, indicating short-term obligations exceed liquid assets.
In addition, Klotho Neurosciences corrected a prior misstatement regarding a stock purchase agreement dated June 5, 2025. The company clarified that it sold 6,250,000 shares of its common stock for a total purchase price of $500,000. This sale was conducted under the exemption from registration provided by Section 4(2) of the Securities Act of 1933, based on the purchaser’s investment intent and sophistication. Trading at a high Price/Book multiple of 102.26, the stock appears overvalued based on InvestingPro Fair Value calculations. Subscribers can access 10 additional ProTips and comprehensive financial metrics to better evaluate this volatile investment.
The company, which underwent name changes from ANEW Medical (TASE:BLWV), Inc. on June 24, 2024, and previously from Redwoods Acquisition Corp. on January 27, 2022, is headquartered in Omaha, Nebraska. It operates under the Delaware jurisdiction and is listed on the Nasdaq Stock Market LLC under the symbols KLTO for its common stock and KLTOW for its warrants.
This announcement is based on the press release statement and the details provided in the SEC filing.
In other recent news, Klotho Neurosciences, Inc. is facing potential delisting from the Nasdaq Stock Market due to non-compliance with listing requirements, specifically the minimum bid price rule. The company was granted an extension until August 13, 2025, to meet these requirements, contingent on achieving specific milestones and reporting progress. Concurrently, Klotho Neurosciences has announced a significant acquisition agreement with SB Security Holdings, LLC, a subsidiary of SkyBell Technologies, Inc. This acquisition, expected to be completed by August 13, 2025, involves Klotho issuing new shares that will constitute 90% of its post-deal common stock to SkyBell. The deal is subject to several conditions, including shareholder approval and Nasdaq clearance. This move marks a strategic shift for Klotho, as it enters the home security market, a departure from its previous focus on biological products. The company’s CEO, Joseph Sinkule, has affirmed Klotho’s commitment to regaining Nasdaq compliance and successfully completing the acquisition.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.